title: Predictive value of brain natriuretic peptide in the diagnosis of heart transplant rejection.
abstract: OBJECTIVE
  To evaluate the pattern of brain natriuretic peptide (BNP) concentration in heart transplant (HT) recipients and its relation to the degree of graft rejection determined by endomyocardial biopsy specimen.
  
  
  METHODS
  We studied 71 consecutive HT recipients (62 men, 53 +/- 11 years). The patients underwent 383 biopsies. Creatinine and BNP concentrations and hemodynamic parameters were determined along with the degree of graft rejection using endomyocardial biopsy specimens. We considered treatable rejection as International Society for Heart and Lung Transplantation Grade >or=2 in the first 90 days and >or=3A thereafter. We included a control group of 36 healthy individuals.
  
  
  RESULTS
  Brain natriuretic peptide concentration was significantly greater among HT recipients (264 +/- 318 pg/ml) than in controls (17 +/- 16 pg/ml). In the first 90 days, BNP concentration was significantly greater among the patients with graft rejection (510 +/- 470, n = 84, vs 278 +/- 255, n = 87; p < 0.0001), although the corresponding discriminatory capacity was small. After the first 90 days, BNP values were similar in patients with and without graft rejection (170 +/- 297, n = 17, vs 142 +/- 203, n = 195; p = not significant). Creatinine concentration increased with time after transplantation and did not correlate with BNP concentration. We observed significant positive correlation between BNP concentration and hemodynamic parameters.
  
  
  CONCLUSIONS
  Brain natriuretic peptide concentration remains increased after HT, with stabilization after the 4th month. Brain natriuretic peptide concentrations are slightly greater among patients with treatable rejection, particularly in the first 90 days, although BNP concentration lacks discriminatory capacity to serve as a guide to performing biopsy.
authors.affiliation: Cardiology La Fe University Hospital, Valencia, Spain. shatto@servitel.es
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Arnau-Vives
authors.forename: Luis
authors.initials: L
authors.lastname: Almenar
authors.forename: Isabel
authors.initials: I
authors.lastname: Hervas
authors.forename: Ana
authors.initials: A
authors.lastname: Osa
authors.forename: Luis
authors.initials: L
authors.lastname: Martinez-Dolz
authors.forename: Joaquin
authors.initials: J
authors.lastname: Rueda
authors.forename: Esther
authors.initials: E
authors.lastname: Zorio
authors.forename: Luis
authors.initials: L
authors.lastname: Martinez-Ortiz De Urbina
authors.forename: Jose L
authors.initials: JL
authors.lastname: Perez
authors.forename: Antonio
authors.initials: A
authors.lastname: Mateo
authors.forename: Miguel
authors.initials: M
authors.lastname: Palencia
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006084:Graft Rejection / Q000097:blood*; D016027:Heart Transplantation / Q000276:immunology* / Q000502:physiology; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D013997:Time Factors
chemical_list: D020097:Natriuretic Peptide, Brain